Jérôme-André Gauthier, new Strategy and Business Development Director >
Jérôme-André Gauthier joins the Executive Committee team at Ceva Santé Animale as the new Strategy and Business Development Director, starting January 1st, 2014.
Ceva acquires Sogeval >
Sogeval, a subsidiary of Sofiprotéol, joins veterinary firm Ceva Santé Animale with a view to creating one of the world leaders in veterinary pharmacy.
Innovation Award for Sleeping Sickness Control campaign's partners >
SOS partners COCTU and COVAB, Makerere given Innovation Award for sleeping sickness control campaign
Ceva and Sogeval in exclusive negotiations to create a global leader in animal health >
Ceva and Sogeval (a subsidiary of Sofiprotéol), based in Laval announce the opening of exclusive negotiations to create a future alliance.
Long term agreement with Jinyu Baoling to produce brucellosis vaccines in China >
Ceva concludes long term agreement with Jinyu Baoling to produce brucellosis vaccines in China
Ceva launches Fertipig® in Asia >
New product gives swine producers “power with control”
Ceva support to the 11th IFCN Dairy Conference >
This year for the 11th time, leading dairy related companies came together at the IFCN Supporter Conference, held September 16th to 18th 2012 in Oxford, UK. IFCN stands for International Farm Comparison Network. This researcher’s organization provides the latest global information on milk production and the overall sector developments.
Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >
Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines
Ceva launches new Vectormune ® website >
Website provides educational resources for poultry professionals, as well as comprehensive information about their vector vaccines range.
Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >
Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines